cardiovascular– tag –
-
Biotech Investment News: Key Pharmaceutical Deals of Otsuka (2015–2025)
Strategic Overview: Otsuka’s Global Expansion in CNS and Rare Diseases Otsuka Pharmaceutical has focused heavily on the central nervous system (CNS), leveraging U.S.-centered M&A and partnerships to expand its product pipeline. In re... -
Biotech Investment News: Novartis’s Key Deals from 2015 to 2025
Strategic Review: From Blockbusters to Nuclear Medicine, Gene and Cell Therapy Over the past decade, Novartis has strategically shifted its focus toward high-value therapies, including nuclear medicine (Pluvicto), gene therapy (Zolgensma... -
Biotech Investment News: Bristol Myers Squibb’s Major Deals (2015–2025)
Strategic Review: From Opdivo to Next-Gen Modalities BMS is known as a pioneer in immuno-oncology, with the development of Opdivo (nivolumab) and Yervoy (ipilimumab). Over the past decade, the company has expanded aggressively into new m... -
Biotech Investment News: Johnson & Johnson’s 10-Year Deal Summary & 2025 Update (2015–2025)
Strategic Review: Immunology, Oncology, and Rare Diseases at the Core of J&J’s R&D-Driven Vision Johnson & Johnson (J&J) has strategically expanded into immunology, oncology, and rare diseases by acquiring biotech compani...
1